Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in NuvaRing, is a combined hormonal contraceptive presented as a vaginal ring delivering ethinylestradiol 0.015 mg/day and etonogestrel 0.12 mg/day for vaginal use. It works to prevent pregnancy in women of reproductive age by inhibiting ovulation, thickening cervical mucus and altering the endometrial lining.

GNH USA supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

NuvaRing, a combined hormonal contraceptive, is indicated for prevention of pregnancy.

- Contraception: provides reliable prevention of pregnancy during typical use.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Breast tenderness: may occur during initial cycles. - Vaginal irritation or discharge: localized reaction to the ring. - Spotting or breakthrough bleeding: irregular bleeding patterns. - Mood changes: mild emotional fluctuations.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Hepatic adenoma or cholestatic jaundice: rare liver complications. - Severe allergic reaction: anaphylaxis, angioedema. - Hypertension: sudden increase in blood pressure. - Ectopic pregnancy: pregnancy occurring outside the uterus.

Before using NuvaRing, consider the following precautions: - Contraindicated in pregnancy: product must not be used by pregnant women. - Smoking restriction: avoid smoking >15 cigarettes per day if age >35 years. - History of thromboembolism: assess risk before prescribing. - Liver disease: use with caution in hepatic impairment. - Breast cancer: contraindicated in active or past breast malignancy. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

NuvaRing may interact with other medicines as follows:

Major Interactions (Avoid): - Rifampin: enzyme inducer that can markedly reduce contraceptive efficacy. - Anticonvulsants (phenytoin, carbamazepine): may lower hormone levels and increase failure risk. - Efavirenz (antiretroviral): can diminish hormonal protection.

Moderate Interactions (Monitor Closely): - Azole antifungals (ketoconazole, itraconazole): may increase hormone concentrations, requiring monitoring. - St. John’s wort: herbal inducer that can decrease effectiveness of the ring.